RAPP official logo RAPP
RAPP 1-star rating from Upturn Advisory
Rapport Therapeutics, Inc. Common Stock (RAPP) company logo

Rapport Therapeutics, Inc. Common Stock (RAPP)

Rapport Therapeutics, Inc. Common Stock (RAPP) 1-star rating from Upturn Advisory
$29.5
Last Close (24-hour delay)
Profit since last BUY0.24%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 7 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

2 star rating from financial analysts

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $51.5

1 Year Target Price $51.5

Analysts Price Target For last 52 week
$51.5 Target price
52w Low $6.43
Current$29.5
52w High $42.27

Analysis of Past Performance

Type Stock
Historic Profit -7.97%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.41B USD
Price to earnings Ratio -
1Y Target Price 51.5
Price to earnings Ratio -
1Y Target Price 51.5
Volume (30-day avg) 5
Beta -
52 Weeks Range 6.43 - 42.27
Updated Date 12/7/2025
52 Weeks Range 6.43 - 42.27
Updated Date 12/7/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.27

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -15.89%
Return on Equity (TTM) -23.41%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 904849571
Price to Sales(TTM) -
Enterprise Value 904849571
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 47661138
Shares Floating 30413049
Shares Outstanding 47661138
Shares Floating 30413049
Percent Insiders 4.68
Percent Institutions 103.88

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock(RAPP) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Rapport Therapeutics is a clinical-stage biotechnology company focusing on developing precision medicines for neurological disorders. Founded in 2022, it aims to address significant unmet needs in epilepsy, pain, and other neurological conditions through targeted therapies.

Company business area logo Core Business Areas

  • Drug Development: Discovery and development of novel therapeutics for neurological disorders, focusing on selective targeting of specific brain circuits and cell types.
  • Precision Medicine: Employing advanced technologies to identify patient subpopulations most likely to benefit from their therapies.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.

leadership logo Leadership and Structure

Rapport Therapeutics is led by a management team with experience in drug development and neuroscience. The organizational structure is typical for a biotech company, with research, development, clinical, and administrative functions.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • RAP-219 (Epilepsy): RAP-219 is Rapport's lead drug candidate, a selective neuronal modulator being developed for drug-resistant focal epilepsy. Currently in Phase 1 clinical trials. Market share data is not yet applicable as the drug is not approved. Competitors include existing anti-epileptic drugs from companies like UCB (UCBJF) and Eisai (ESALY), as well as other companies developing novel therapies like SK Biopharmaceuticals (326030.KS).
  • RAP-198 (Neuropathic Pain): RAP-198 is being developed for neuropathic pain. Currently in preclinical stages. Market share data is not yet applicable as the drug is not approved. Competitors include pharmaceutical companies selling pain medications such as Pfizer (PFE), Eli Lilly (LLY), and Johnson & Johnson (JNJ), as well as companies developing novel pain therapies like Vertex Pharmaceuticals (VRTX).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on neurological disorders is characterized by high unmet medical needs, significant market potential, and intense competition. Advances in neuroscience and drug development technologies are driving innovation.

Positioning

Rapport Therapeutics is positioned as an innovator in precision neuroscience, focusing on developing targeted therapies for specific patient populations. Their competitive advantage lies in their ability to selectively modulate neuronal activity to address the underlying causes of neurological disorders.

Total Addressable Market (TAM)

The global market for epilepsy and neuropathic pain treatments are estimated at billions of dollars annually. Rapport Therapeutics aims to capture a significant share of this market by developing more effective and targeted therapies. The epilepsy market is projected to reach $12.1 billion by 2029. Rapport is positioned to access this TAM pending successful trials and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Strong scientific expertise in neuroscience
  • Proprietary technology platform for precision drug development
  • Experienced management team
  • Promising lead drug candidate (RAP-219)

Weaknesses

  • Early-stage company with limited revenue
  • High reliance on clinical trial success
  • Limited financial resources compared to larger pharmaceutical companies
  • Drug development is very uncertain

Opportunities

  • Large unmet medical need in neurological disorders
  • Potential for partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas within neuroscience
  • Positive clinical trial results could lead to significant market value increase

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Patent challenges

Competitors and Market Share

Key competitor logo Key Competitors

  • UCBJF
  • ESALY
  • PFE
  • LLY
  • JNJ
  • VRTX
  • SK Biopharmaceuticals(326030.KS)

Competitive Landscape

Rapport Therapeutics competes with established pharmaceutical companies and other biotech companies developing therapies for neurological disorders. Their advantage lies in their precision medicine approach, but they face challenges related to clinical trial execution and funding.

Growth Trajectory and Initiatives

Historical Growth: Limited historical growth data is available due to the company's recent founding.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections vary widely based on the potential of their drug candidates.

Recent Initiatives: Recent initiatives include advancing RAP-219 into Phase 1 clinical trials and expanding its pipeline of drug candidates.

Summary

Rapport Therapeutics is an early-stage biotech company with a promising pipeline of precision medicines for neurological disorders. Their focus on selective neuronal modulation and experienced management team are strengths. However, they face typical challenges associated with drug development, including clinical trial risk and competition from larger companies. They need to secure funding and execute clinical trials successfully to achieve their growth potential.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings (e.g., S-1)
  • Industry reports
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor. Market share estimates are approximate and may vary depending on the source.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Rapport Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2024-06-07
CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 69
Full time employees 69

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.